Humanized anti-CD134 (OX40) antibodies and uses thereof
AssigneesBiocerox Products B.V., Janssen Pharmaceuticals, Inc.
InventorsPetrus Johannes Simons, Louis Boon, Jinquan Luo, Randall Brezski, Monica Goldberg
Life of this patent
Estimating the term…
Abstract
The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
Claims7
An isolated antibody that binds human CD134, comprising a light chain variable region (VL) and a heavy chain variable region (VH), wherein the VL comprises SEQ ID NO:63 and the VH comprises SEQ ID NO:66.
Dependencies are inferred from the claim text.